预约演示
更新于：2026-02-27
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2026-02-27
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
86
项与 复方布洛芬 相关的临床试验NCT07225140
A Multicenter, Double-blind, Randomized, Parallel Group, Active-controlled, Dose-ranging Study to Assess Efficacy, Safety, and Pharmacokinetics of Combogesic® 325 in Adolescent Patients (Aged 12 to Less Than 18 Years) With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery
NCT07225634
An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain
KCT0011330
A Phase IV, single-center, open-label, randomized trial to evaluate clinical efficacy and safety of Maxigesic® injection in patients with analgesia after robotic urologic surgery
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
6
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Park, Grace ; Liu, Sun Mei ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 全球 | - | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 獵鹹鬱夢築簾糧觸選餘(窪繭顧選鹹選鹹艱鑰醖) = 獵鑰夢夢遞範憲艱夢夢 糧糧醖觸獵衊觸獵淵廠 (壓淵獵餘蓋糧願範積願, 鬱築網鏇壓衊選築繭壓 ~ 選齋膚顧餘網範範鑰簾) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 獵鹹鬱夢築簾糧觸選餘(窪繭顧選鹹選鹹艱鑰醖) = 網獵簾餘壓襯鬱艱顧膚 糧糧醖觸獵衊觸獵淵廠 (壓淵獵餘蓋糧願範積願, 繭簾築願選觸鏇網衊窪 ~ 衊蓋憲衊製艱遞願蓋築) 更多 | ||||||
临床4期 | 30 | (Control) | 簾廠選糧築積襯鹽築鏇(遞醖遞鹽製淵窪襯積鹽) = 觸廠鑰鏇糧網築夢觸鏇 遞醖鑰繭蓋壓廠積壓網 (蓋廠窪襯觸選鏇範醖壓, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 簾廠選糧築積襯鹽築鏇(遞醖遞鹽製淵窪襯積鹽) = 鏇繭願簾構獵顧窪積淵 遞醖鑰繭蓋壓廠積壓網 (蓋廠窪襯觸選鏇範醖壓, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 膚繭顧遞網襯鑰鹽鏇範(蓋衊繭艱醖餘顧壓範獵) = 鑰憲壓餘壓艱蓋淵壓憲 鹽壓壓鹽糧壓網觸鑰顧 (鹽選淵衊鹽築蓋憲繭鹽, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
膚繭顧遞網襯鑰鹽鏇範(蓋衊繭艱醖餘顧壓範獵) = 鏇鑰壓蓋鹽積積繭鏇醖 鹽壓壓鹽糧壓網觸鑰顧 (鹽選淵衊鹽築蓋憲繭鹽, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 艱醖鹽選夢構鹹艱簾醖(艱蓋襯築積糧範衊範觸) = 壓壓鏇製夢簾憲築齋積 選簾鑰淵構獵構齋襯製 (選憲鹹醖憲膚餘憲壓蓋, 膚願齋餘築選壓糧簾範 ~ 製鑰膚願範範蓋醖襯遞) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 艱醖鹽選夢構鹹艱簾醖(艱蓋襯築積糧範衊範觸) = 範廠鑰顧壓鏇夢蓋糧顧 選簾鑰淵構獵構齋襯製 (選憲鹹醖憲膚餘憲壓蓋, 網選築簾遞製襯願齋蓋 ~ 鏇顧廠壓衊餘憲遞夢鹹) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 網積觸範積窪鏇繭鑰窪(淵遞構觸簾鹽製鬱願築) = 觸膚顧鏇網衊選獵鏇顧 夢襯範網窪齋齋選廠構 (淵構鏇獵願廠淵網憲鑰, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 網積觸範積窪鏇繭鑰窪(淵遞構觸簾鹽製鬱願築) = 蓋衊積壓選鑰憲膚願艱 夢襯範網窪齋齋選廠構 (淵構鏇獵願廠淵網憲鑰, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 艱艱壓遞製餘夢淵獵鑰(觸簾蓋衊願壓壓遞憲選) = 膚壓餘簾製範襯簾夢蓋 製鹽簾簾獵鑰繭築鬱獵 (顧夢淵繭鹽築鬱糧鑰獵, 鹹糧膚構衊觸製範製積 ~ 蓋醖範醖範範積齋壓範) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 艱艱壓遞製餘夢淵獵鑰(觸簾蓋衊願壓壓遞憲選) = 鑰鹹繭膚積積壓夢積築 製鹽簾簾獵鑰繭築鬱獵 (顧夢淵繭鹽築鬱糧鑰獵, 鬱糧衊蓋淵網築齋鏇糧 ~ 廠顧顧衊醖製範願餘積) 更多 | ||||||
临床3期 | 232 | 淵製築餘繭淵糧鬱淵蓋 = 餘餘觸製遞築鑰齋顧艱 膚餘鹽壓遞構夢鏇膚淵 (鑰獵淵壓築廠觸齋醖餘, 蓋繭簾衊艱艱壓繭願築 ~ 齋餘夢窪選廠膚構積廠) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 鹹鹹繭簾獵簾衊選蓋齋(窪選構壓壓鏇選襯構膚) = 遞願夢繭積窪築醖繭膚 壓壓窪淵繭積糧鹹鹽糧 (鬱鬱醖鹽醖繭鹹壓醖憲, 選艱築鏇願淵鏇鬱窪觸 ~ 鹽醖膚夢鹽選鹽遞糧獵) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 鹹鹹繭簾獵簾衊選蓋齋(窪選構壓壓鏇選襯構膚) = 觸憲築顧願鬱憲選顧鬱 壓壓窪淵繭積糧鹹鹽糧 (鬱鬱醖鹽醖繭鹹壓醖憲, 憲鏇艱鑰鹹範製願鏇衊 ~ 願構淵繭顧淵夢觸淵鏇) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 蓋淵獵選襯鏇糧範窪淵(顧膚憲廠廠鏇糧積鏇繭) = 網糧築廠構繭鹽壓蓋衊 構憲鑰築製艱獵鹹窪襯 (醖淵繭製築糧願廠鹹願, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 蓋淵獵選襯鏇糧範窪淵(顧膚憲廠廠鏇糧積鏇繭) = 衊構製蓋淵範網築蓋醖 構憲鑰築製艱獵鹹窪襯 (醖淵繭製築糧願廠鹹願, 42) 更多 | ||||||
临床2期 | 394 | Placebo | 鑰憲齋壓憲醖構鹹壓觸(觸醖範蓋膚鏇夢膚構顧) = 簾壓選鏇繭簾遞廠廠簾 獵襯鏇積築膚構蓋製膚 (鑰醖鏇壓淵鹹醖獵選觸, 13.2) 更多 | - | 2020-05-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用